Form 4: Applied Therapeutics Director Teena Lerner Granted 200,000 Stock Options

Applied Therapeutics, Inc. Director Teena Lerner was granted 200,000 stock options with an exercise price of $0.395, vesting over 36 months.

Summary

• Teena Lerner, a Director of Applied Therapeutics, Inc. (APLT), was granted 200,000 stock options.
• The options have an exercise price of $0.395 per share.
• These options will vest in 36 equal monthly installments from the grant date, contingent on Ms. Lerner's continuous service.
• The grant date for these options was June 9, 2025, and they are set to expire on June 9, 2035.
• Following this transaction, Ms. Lerner beneficially owns 200,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning management incentives with shareholder value creation and for retaining key board members.

Positives

• The grant of 200,000 stock options to Director Teena Lerner aligns her interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over 36 months promotes retention of key board members.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if exercised.

Risks

• The value of the stock options is dependent on the future stock price of Applied Therapeutics, Inc. exceeding the exercise price of $0.395.
• The vesting of options is subject to the director's continuous service, meaning unvested options would be forfeited upon departure.

Future Outlook

The vesting schedule of the stock options over 36 months indicates an expectation of continued service from the director and a long-term incentive structure.

Management Comments

• "The shares subject to the option will vest in 36 equal monthly installments from the grant date, subject to the Reporting Person's continuous service through such vesting date."
• The filing was signed by Leslie D. Funtleyder as attorney-in-fact for Teena Lerner, indicating a formal process for SEC filings.

Industry Context

This is a standard insider transaction report (Form 4) for a director receiving equity compensation. Such grants are common practice in the biotechnology and pharmaceutical industries to attract and retain talent, aligning management and board interests with shareholder value creation.

Corporate Governance

Related Party Transactions

• The stock option grant to Teena Lerner, a director, is an insider transaction, which is a form of related party dealing.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also increased alignment of director's interests with shareholder value.

Next Steps

• Continued service of Teena Lerner to ensure vesting of the stock options over the next 36 months.
• Potential exercise of options by Teena Lerner if the stock price exceeds the exercise price of $0.395 before the expiration date.

Key Dates

Recommendation

Keywords

Applied Therapeutics, APLT, Stock Option Grant, Insider Transaction, Form 4, Director Compensation, Equity Incentive, Teena Lerner, Beneficial Ownership